HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Codeine/Ibuprofen Combination Drugs Should Be Rx-Only, Says EMA

Executive Summary

Prompted by reports of abuse leading to deaths, the European Medicines Agency's PRAC is recommending that combination drugs containing codeine and ibuprofen be reverse-switched across the EU to prescription-only status.

You may also be interested in...

OTC Codeine Cough Syrups Meet UK Conditions For Rx Reverse Switch, Says Expert Body

Could codiene linctus cough syrups be reverse-switched from OTC to Rx status in the UK? A panel of independent medicines experts suggests they should be, based on UK drugs law and their use in illegal cocktail Purple Drank.

Dutch Parliament To Decide Future Of OTC Market

In January, the Dutch Parliament will debate an amendment to the country's medicines legislation that proposes to remove the requirement for a druggist or assistant druggist to be physically present during the sale of self-care medicines. The move will once again allow supermarkets to sell UAD medicines, with the help of digital tablets offering professional advice, hastening the transformation of the Dutch OTC market, according to Neprofarm's Bernard Mauritz.

Ireland Reviewing Codeine's OTC Status

Ireland’s drug regulator HPRA has initiated a formal regulatory procedure to determine if OTC remains the appropriate classification for codeine-containing products. The agency says the move is in response to a growing understanding of the potential impacts of addiction to codeine at low doses.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts